Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

• ClinicalTrials.gov Identifier: NCT00916747
• Recruitment Status: Active, not recruiting
• First Posted: June 9, 2009
• Last Update Posted: February 27, 2023
• Sponsor: Boston Children's Hospital
• Collaborators: Schering-Plough; Merck Sharp & Dohme LLC; Eiger BioPharmaceuticals
• Information provided by (Responsible Party): Monica E. Kleinman, Boston Children's Hospital

Tracking Information

• First Submitted Date: June 5, 2009
• First Posted Date: June 9, 2009
• Last Update Posted Date: February 27, 2023
• Study Start Date: August 2009
• Actual Primary Completion Date: February 2022 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: June 5, 2009): To evaluate the therapeutic effects of the combination of zoledronic acid, pravastatin and lonafarnib in patients with HGPS. [ Time Frame: 2 years ]
• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: June 5, 2009)

• To describe any acute and chronic toxicities associated with treating progeria patients with the combination of zoledronic acid, pravastatin and lonafarnib. [ Time Frame: 2 years ]
• To investigate which clinical and laboratory studies are needed to monitor or alter therapy to prevent unacceptable toxicity. [ Time Frame: 2 years ]
• To assess the pharmacokinetics of lonafarnib in patients with progeria. [ Time Frame: 2 years ]
• To assay for the inhibition of HDJ-2 farnesylation in Peripheral Blood Leukocytes (PBL). [ Time Frame: 2 years ]
• To assay for changes in research-based potential markers of efficacy such as levels of prelamin A, mature lamin A, progerin, and HP1 in protein isolated from PBL. [ Time Frame: 2 years ]
• To assess changes in leptin levels, glucose utilization, skeletal abnormalities including bone mineral density and X-ray finding, joint contracture and function, and growth [ Time Frame: 2 years ]
• To assess changes in auditory function, dental anomalies, dermatologic changes including hair density, nutrition with calorie analysis and energy expenditure, body composition analysis by DXA scan, and cardiovascular structure and function. [ Time Frame: 2 years ]
• To compare and incorporate clinical and laboratory data obtain from this study with that obtained during the single agent lonafarnib trial as well as the pilot combination trial of zoledronic acid, pravastatin and lonafarnib [ Time Frame: 2 years ]

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
• Official Title: An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid Laminopathies
• Brief Summary: Hutchinson-Gilford Progeria Syndrome (Progeria) is a rare autosomal disease that results in premature death at a median age of 13 years due to cardiovascular and cerebralvascular compromise. The mutation for this disease has been identified and results in a mutant form of lamin A that cannot be de-farnesylated. This study evaluates the combination of pravastain (a statin), lonafarnib (a farnesyltransferase inhibitor) and zoledronic acid (a bisphosphonate) in an open label phase II efficacy trial in children with Progeria. These agents all target farnesylation pathways at different points. Patients with genetically confirmed progeria will be eligible for this protocol. Treatment will be initiated for 24 months duration. Clinical and biologic parameters will be examined to assess response.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 2

Study Design

Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Masking Description:

Open Label

Primary Purpose: Treatment

• Condition: Progeria

Intervention

Drug: Lonafarnib, Zoledronic Acid, and Pravastatin

Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus.

Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period.

Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily.

Study Arms

Experimental: Treatment arm

All patients will receive zoledronic acid, pravastatin and lonafarnib

Intervention: Drug: Lonafarnib, Zoledronic Acid, and Pravastatin

Publications *

• Gordon LB, Kleinman ME, Massaro J, D'Agostino RB Sr, Shappell H, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland RH, Nazarian A, Snyder BD, Ullrich NJ, Silvera VM, Liang MG, Quinn N, Miller DT, Huh SY, Dowton AA, Littlefield K, Greer MM, Kieran MW. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation. 2016 Jul 12;134(2):114-25. doi: 10.1161/CIRCULATIONAHA.116.022188.
• Gordon LB, Massaro J, D'Agostino RB Sr, Campbell SE, Brazier J, Brown WT, Kleinman ME, Kieran MW; Progeria Clinical Trials Collaborative. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation. 2014 Jul 1;130(1):27-34. doi: 10.1161/CIRCULATIONAHA.113.008285. Epub 2014 May 2.

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: April 14, 2017): 85
• Original Estimated Enrollment (submitted: June 5, 2009): 45
• Estimated Study Completion Date: December 2023
• Actual Primary Completion Date: February 2022 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Genetic Diagnosis: All patients must have confirmatory mutational analysis showing mutation in the lamin A gene.
• Clinical Diagnosis: Patients must display clinical signs of progeria as per the clinical trial team.
• Travel: Patients must be willing and able to come to Boston for appropriate studies and examinations at initiation of study and at months 6, 12, 18 and 24 on study.
• Patient must have adequate organ and marrow function as defined by the following parameters:
• Blood: APC (ANC + bands + monocytes = APC) > 1,000/microliters, Platelets > 75,000/microliters (transfusion independent); Hemoglobin >9g/dl.
• Renal: creatinine Less than or equal 1.5 times normal for age or GFR > 70 ml/min/1.73m2.
• Hepatic: bilirubin Less than or equal to 1.5 x upper limit of normal for age; SGPT (ALT) < and SGOT (AST) < 5 x normal range for age.
• PT/PTT: PT/PTT < 120% upper limit of normal OR PI approval
• No overt renal, hepatic, pulmonary disease or immune dysfunction.
• 25-hydroxyvitamin D ≥ 20 ng/ml within 4 weeks of bisphosphonate infusion.
• Signed informed consent according to institutional guidelines must be obtained and patient must begin therapy within twenty eight (28) days.

Exclusion Criteria:

• Other than the drugs used in this protocol, drugs targeted to treat Progeria are excluded. Drugs to treat symptoms of Progeria are permitted.
• Patients must not be taking medications that significantly affect the metabolism of lonafarnib at the time they start lonafarnib
• Patient must have no uncontrolled infection.
• Subjects who have known or suspected hypersensitivity to any of the excipients included in the formulation should not be treated.
• Patients must not be pregnant or breast-feeding. Female patients of childbearing potential must have negative serum or urine pregnancy test. Male and female patients of reproductive potential must agree to use a medically accepted form of birth control while on study and up to 10 weeks after treatment. It is permissible for female patients to take oral contraceptives or other hormonal methods while receiving treatment with lonafarnib.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: Child, Adult, Older Adult
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT00916747
• Other Study ID Numbers: Progeria Efficacy
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Monica E. Kleinman, Boston Children's Hospital
• Original Responsible Party: Mark Kieran, MD, PhD, Children's Hospital Boston/ Dana-Farber Cancer Institute
• Current Study Sponsor: Boston Children's Hospital
• Original Study Sponsor: Same as current

Collaborators

• Schering-Plough
• Merck Sharp & Dohme LLC
• Eiger BioPharmaceuticals

Investigators

• Principal Investigator: Mark Kieran, MD, PhD; Children's Hospital Boston/ Dana-Farber Cancer Instittue

• PRS Account: Boston Children's Hospital
• Verification Date: February 2023